Iris Kramer1,2, Michael Schaapveld, Hester S A Oldenburg3, Gabe S Sonke4, Danielle McCool, Flora E van Leeuwen, Koen K Van de Vijver5, Nicola S Russell6, Sabine C Linn4,7, Sabine Siesling8,9, C Willemien Menke-van der Houven van Oordt10, Marjanka K Schmidt1,2. 1. Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 2. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 3. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 4. Department of Surgical Oncology. 5. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 6. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 7. Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands. 8. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. 9. Department of Health Technology and Service Research, Technical Medical Center, University of Twente, Enschede, the Netherlands. 10. Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: An increasing number of breast cancer (BC) survivors are at risk of developing contralateral breast cancer (CBC). We aimed to investigate the influence of various adjuvant systemic regimens on, subtype-specific, risk of CBC. METHODS: This population-based cohort study included female patients diagnosed with first invasive BC between 2003 and 2010; follow-up was complete until 2016. Clinico-pathological data were obtained from the Netherlands Cancer Registry and additional data on receptor status through linkage with PALGA: the Dutch Pathology Registry. Cumulative incidences (death and distant metastases as competing risk) and hazard ratios (HRs) were estimated for all invasive metachronous CBC and CBC subtypes. RESULTS: Of 83 144 BC patients, 2816 developed a CBC; the 10-year cumulative incidence was 3.8% (95% confidence interval [CI] = 3.7% to 4.0%). Overall, adjuvant chemotherapy (HR = 0.70, 95% CI = 0.62 to 0.80), endocrine therapy (HR = 0.46, 95% CI = 0.41 to 0.52), and trastuzumab with chemotherapy (HR = 0.57, 95% CI = 0.45 to 0.73) were strongly associated with a reduced CBC risk. Specifically, taxane-containing chemotherapy (HR = 0.48, 95% CI = 0.36 to 0.62) and aromatase inhibitors (HR = 0.32, 95% CI = 0.23 to 0.44) were associated with a large CBC risk reduction. More detailed analyses showed that endocrine therapy statistically significantly decreased the risk of estrogen receptor (ER)-positive CBC (HR = 0.41, 95% CI = 0.36 to 0.47) but not ER-negative CBC (HR = 1.32, 95% CI = 0.90 to 1.93) compared with no endocrine therapy. Patients receiving chemotherapy for ER-negative first BC had a higher risk of ER-negative CBC from 5 years of follow-up (HR = 2.84, 95% CI = 1.62 to 4.99) compared with patients not receiving chemotherapy for ER-negative first BC. CONCLUSION: Endocrine therapy, chemotherapy, as well as trastuzumab with chemotherapy reduce CBC risk. However, each adjuvant therapy regimen had a different impact on the CBC subtype distribution. Taxane-containing chemotherapy and aromatase inhibitors were associated with the largest CBC risk reduction.
BACKGROUND: An increasing number of breast cancer (BC) survivors are at risk of developing contralateral breast cancer (CBC). We aimed to investigate the influence of various adjuvant systemic regimens on, subtype-specific, risk of CBC. METHODS: This population-based cohort study included female patients diagnosed with first invasive BC between 2003 and 2010; follow-up was complete until 2016. Clinico-pathological data were obtained from the Netherlands Cancer Registry and additional data on receptor status through linkage with PALGA: the Dutch Pathology Registry. Cumulative incidences (death and distant metastases as competing risk) and hazard ratios (HRs) were estimated for all invasive metachronous CBC and CBC subtypes. RESULTS: Of 83 144 BC patients, 2816 developed a CBC; the 10-year cumulative incidence was 3.8% (95% confidence interval [CI] = 3.7% to 4.0%). Overall, adjuvant chemotherapy (HR = 0.70, 95% CI = 0.62 to 0.80), endocrine therapy (HR = 0.46, 95% CI = 0.41 to 0.52), and trastuzumab with chemotherapy (HR = 0.57, 95% CI = 0.45 to 0.73) were strongly associated with a reduced CBC risk. Specifically, taxane-containing chemotherapy (HR = 0.48, 95% CI = 0.36 to 0.62) and aromatase inhibitors (HR = 0.32, 95% CI = 0.23 to 0.44) were associated with a large CBC risk reduction. More detailed analyses showed that endocrine therapy statistically significantly decreased the risk of estrogen receptor (ER)-positive CBC (HR = 0.41, 95% CI = 0.36 to 0.47) but not ER-negative CBC (HR = 1.32, 95% CI = 0.90 to 1.93) compared with no endocrine therapy. Patients receiving chemotherapy for ER-negative first BC had a higher risk of ER-negative CBC from 5 years of follow-up (HR = 2.84, 95% CI = 1.62 to 4.99) compared with patients not receiving chemotherapy for ER-negative first BC. CONCLUSION: Endocrine therapy, chemotherapy, as well as trastuzumab with chemotherapy reduce CBC risk. However, each adjuvant therapy regimen had a different impact on the CBC subtype distribution. Taxane-containing chemotherapy and aromatase inhibitors were associated with the largest CBC risk reduction.
Authors: Shoshana M Rosenberg; Mary L Greaney; Andrea F Patenaude; Ann H Partridge Journal: J Adolesc Young Adult Oncol Date: 2019-04-03 Impact factor: 2.223
Authors: Daniele Giardiello; Maartje J Hooning; Michael Hauptmann; Renske Keeman; B A M Heemskerk-Gerritsen; Heiko Becher; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Nicola J Camp; Kamila Czene; Peter Devilee; Diana M Eccles; Peter A Fasching; Jonine D Figueroa; Henrik Flyger; Montserrat García-Closas; Christopher A Haiman; Ute Hamann; John L Hopper; Anna Jakubowska; Floor E Leeuwen; Annika Lindblom; Jan Lubiński; Sara Margolin; Maria Elena Martinez; Heli Nevanlinna; Ines Nevelsteen; Saskia Pelders; Paul D P Pharoah; Sabine Siesling; Melissa C Southey; Annemieke H van der Hout; Liselotte P van Hest; Jenny Chang-Claude; Per Hall; Douglas F Easton; Ewout W Steyerberg; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2022-10-21 Impact factor: 8.408
Authors: Gordon P Watt; Esther M John; Elisa V Bandera; Kathleen E Malone; Charles F Lynch; Julie R Palmer; Julia A Knight; Melissa A Troester; Jonine L Bernstein Journal: Int J Cancer Date: 2021-02-24 Impact factor: 7.316
Authors: Gordon P Watt; Anne S Reiner; Susan A Smith; Daniel O Stram; Marinela Capanu; Kathleen E Malone; Charles F Lynch; Esther M John; Julia A Knight; Lene Mellemkjær; Leslie Bernstein; Jennifer D Brooks; Meghan Woods; Xiaolin Liang; Robert W Haile; Nadeem Riaz; David V Conti; Mark Robson; David Duggan; John D Boice; Roy E Shore; Marc Tischkowitz; Irene Orlow; Duncan C Thomas; Patrick Concannon; Jonine L Bernstein Journal: JAMA Netw Open Date: 2019-09-04
Authors: Iris Kramer; Maartje J Hooning; Nasim Mavaddat; Michael Hauptmann; Renske Keeman; Ewout W Steyerberg; Daniele Giardiello; Antonis C Antoniou; Paul D P Pharoah; Sander Canisius; Zumuruda Abu-Ful; Irene L Andrulis; Hoda Anton-Culver; Kristan J Aronson; Annelie Augustinsson; Heiko Becher; Matthias W Beckmann; Sabine Behrens; Javier Benitez; Marina Bermisheva; Natalia V Bogdanova; Stig E Bojesen; Manjeet K Bolla; Bernardo Bonanni; Hiltrud Brauch; Michael Bremer; Sara Y Brucker; Barbara Burwinkel; Jose E Castelao; Tsun L Chan; Jenny Chang-Claude; Stephen J Chanock; Georgia Chenevix-Trench; Ji-Yeob Choi; Christine L Clarke; J Margriet Collée; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Mary B Daly; Peter Devilee; Thilo Dörk; Isabel Dos-Santos-Silva; Alison M Dunning; Miriam Dwek; Diana M Eccles; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Montserrat García-Closas; José A García-Sáenz; Graham G Giles; David E Goldgar; Anna González-Neira; Christopher A Haiman; Niclas Håkansson; Ute Hamann; Mikael Hartman; Bernadette A M Heemskerk-Gerritsen; Antoinette Hollestelle; John L Hopper; Ming-Feng Hou; Anthony Howell; Hidemi Ito; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Esther M John; Audrey Jung; Daehee Kang; C Marleen Kets; Elza Khusnutdinova; Yon-Dschun Ko; Vessela N Kristensen; Allison W Kurian; Ava Kwong; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Keitaro Matsuo; Dimitrios Mavroudis; Alfons Meindl; Roger L Milne; Anna Marie Mulligan; Taru A Muranen; Susan L Neuhausen; Heli Nevanlinna; William G Newman; Andrew F Olshan; Janet E Olson; Håkan Olsson; Tjoung-Won Park-Simon; Julian Peto; Christos Petridis; Dijana Plaseska-Karanfilska; Nadege Presneau; Katri Pylkäs; Paolo Radice; Gad Rennert; Atocha Romero; Rebecca Roylance; Emmanouil Saloustros; Elinor J Sawyer; Rita K Schmutzler; Lukas Schwentner; Christopher Scott; Mee-Hoong See; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Sabine Siesling; Susan Slager; Christof Sohn; Melissa C Southey; John J Spinelli; Jennifer Stone; William J Tapper; Maria Tengström; Soo Hwang Teo; Mary Beth Terry; Rob A E M Tollenaar; Ian Tomlinson; Melissa A Troester; Celine M Vachon; Chantal van Ongeval; Elke M van Veen; Robert Winqvist; Alicja Wolk; Wei Zheng; Argyrios Ziogas; Douglas F Easton; Per Hall; Marjanka K Schmidt Journal: Am J Hum Genet Date: 2020-10-05 Impact factor: 11.025